ICM
REGN icon

IMS Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

IMS Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-280
Closed -$246K – 154
2023
Q4 		$246K Hold
280
– – 0.12% 128
2023
Q3 		$230K Hold
280
– – 0.14% 118
2023
Q2 		$201K Hold
280
– – 0.11% 126
2023
Q1 		$230K Hold
280
– – 0.14% 131
2022
Q4 		$202K Buy
+280
New +$207K 0.13% 136
2018
Q4 		– Sell
-30
Closed -$12K – 300
2018
Q3 		$12K Buy
+30
New +$11.4K 0.01% 300

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

IMS Capital Management's REGN Position: Q1 2024 in Review

IMS Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2024, closing a stake of 280 shares — an estimated $246K sold.

IMS Capital Management first reported a position in REGN in Q3 2018 and held it in 6 quarters. The position peaked at $246K in Q4 2023. 1,309 funds tracked by Wall St. Rank hold REGN as of Q1 2024.

  • IMS Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • IMS Capital Management sold 280 Regeneron Pharmaceuticals shares in Q1 2024, an estimated $246K.
  • IMS Capital Management first reported a position in Regeneron Pharmaceuticals in Q3 2018 and held it in 6 quarters.
  • IMS Capital Management's Regeneron Pharmaceuticals position peaked at $246K in Q4 2023.
  • 1,309 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2024.

Based on IMS Capital Management's 13F filing for Q1 2024, filed 13 Jun 2024.